Close Menu

NEW YORK — Grail said today that it will collaborate with three global pharmaceutical firms — Amgen, AstraZeneca, and Bristol Myers Squibb — to evaluate its methylation-based technology for the detection of minimal residual disease in early-stage cancer patients.

Blood-based genomic tests to detect MRD have emerged rapidly in recent years, with multiple companies exploring a variety of platforms. The most prominent so far have been assays like Natera's Signatera, which use sequencing data from tumor tissue samples to develop patient-specific liquid biopsy assays.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.